Piper Sandler analyst Biren Amin maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating, and adjusts the target price from $200 to $182.
According to TipRanks data, the analyst has a success rate of 42.8% and a total average return of 0.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following Sarepta's announcement of a licensing agreement with Arrowhead, an analyst noted the agreement, which includes four clinical and three preclinical programs, accompanied by an upfront payment of $500M and a $325M equity investment, could substantially enhance the company's pipeline. This development potentially offers additional revenue streams beyond its DMD franchise over the long term. The arrangement is viewed positively as it could address concerns regarding Sarepta's need for diversification beyond singular gene therapy approaches.
The partnership with Arrowhead provides Sarepta with platform diversification and a long-term investment in strategies for rare diseases across various therapeutic areas including muscle, central nervous system, and pulmonary conditions. This strategy aligns well with Sarepta's established expertise in rare genetic medicine. Further positive sentiment is derived from the firm's share buyback program, indicating a strong confidence in impending revenue prospects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
